Kalli C Catcott

7PUBLICATIONS
61CO-AUTHORS
Biologically active moleculesAllergyCharacterisation of biological macromoleculesPharmaceutical delivery technologiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 03, 2025
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells.

Raghida A Bukhalid, Jeremy R Duvall, Kelly Lancaster

|Jul 11, 2024
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses.

Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James

|Feb 14, 2024
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.

Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin

|Sep 29, 2023
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.

Susan M Clardy, Alex Uttard, Bingfan Du

|Jul 24, 2023
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates.

Jeremy R Duvall, Joshua D Thomas, Raghida A Bukhalid

|Jun 09, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.

Dorin Toader, Shawn P Fessler, Scott D Collins

Pageof 2

Frequent Collaborators

5 joint publications

Marc Damelin

5 joint publications

Timothy B Lowinger

4 joint publications

Dorin Toader

4 joint publications

Ling Xu